Skip to main content
. 2022 Jul 11;77(10):2729–2736. doi: 10.1093/jac/dkac229

Figure 2.

Figure 2.

Concentration versus time at short-term PK assessment of noFHT and sFHT participants. Plasma tenofovir (TFV) and emtricitabine (FTC) at pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 h in TGW are shown in (a) and (b), respectively, for noFHT participants (no FHT, PrEP only; circles, n = 12) and sFHT participants (PrEP plus standardized FHT; squares, n = 18). Data are means with error bars indicating SDs.